clobazam · Cosette · NDA 210833
Sympazan
Earliest generic entry, as listed · earliest of 3 marketed strengths
31 Jan 2040
Blocked by patent: US 11541002.
Listed patents · 3 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11541002 | product, use U-724 | 31 Jan 2040 |
| US 12290597 | product, use U-724 | 5 Sep 2039 |
| US 12403090 | product, use U-724 | 5 Sep 2039 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 210833 · 001 · RLD | film, oral | 5MG | 31 Jan 2040 |
| 210833 · 002 · RLD | film, oral | 10MG | 31 Jan 2040 |
| 210833 · 003 · RLD | film, oral | 20MG | 31 Jan 2040 |